Fixed dose drug combinations: Issues and challenges in India.
作者信息
Gupta Yogendra Kumar, Ramachandran Suganthi S
机构信息
Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India E-mail:
出版信息
Indian J Pharmacol. 2016 Jul-Aug;48(4):347-349. doi: 10.4103/0253-7613.186200.
Abstract
摘要
相似文献
1
Fixed dose drug combinations: Issues and challenges in India.固定剂量复方制剂：印度面临的问题与挑战
Indian J Pharmacol. 2016 Jul-Aug;48(4):347-349. doi: 10.4103/0253-7613.186200.
2
India signals crackdown on dubious fixed dose drug combinations.印度发出打击可疑固定剂量复方药物的信号。
BMJ. 2013 Jul 17;347:f4588. doi: 10.1136/bmj.f4588.
3
Taking TRIPS to India--Novartis, patent law, and access to medicines.前往印度的《与贸易有关的知识产权协定》之行——诺华公司、专利法与药品可及性
N Engl J Med. 2007 Feb 8;356(6):541-3. doi: 10.1056/NEJMp068245.
4
Issues in Indian science.印度科学中的问题。
Science. 2005 Jul 22;309(5734):557-8; author reply 557-8.
5
America's drug problem.美国的毒品问题。
Hastings Cent Rep. 2012 Jul-Aug;42(4):9-10. doi: 10.1002/hast.59.
6
Bayer challenges India's first compulsory licence for generic version of cancer drug.拜耳对印度首个癌症药物仿制药强制许可提出质疑。
BMJ. 2012 Sep 6;345:e6015. doi: 10.1136/bmj.e6015.
7
Fixed-dose combinations banned in India: is it the right decision? An eye-opening review.固定剂量复方制剂在印度被禁用：这是正确的决定吗？一篇发人深省的综述。
Expert Opin Drug Saf. 2019 Oct;18(10):977-985. doi: 10.1080/14740338.2019.1651292. Epub 2019 Aug 7.
8
Novartis challenges India's drug patent laws in Supreme Court.诺华在最高法院对印度的药品专利法提出质疑。
BMJ. 2012 Feb 21;344:e1279. doi: 10.1136/bmj.e1279.
9
[Problems with high-dose estrogen/progestin combinations such as Mestrogen, in India].[印度高剂量雌激素/孕激素组合药物（如美雌醇）存在的问题]
Ned Tijdschr Geneeskd. 1988 Jan 2;132(1):29-31.
10
Intellectual property. Challenges to India's pharmaceutical patent laws.知识产权。印度制药专利法面临的挑战。
Science. 2012 Jul 27;337(6093):414-5. doi: 10.1126/science.1224892. Epub 2012 Jul 5.
引用本文的文献
1
A critical evaluation of available explicit deprescribing tools for their applicability to Indian elderly patients: a scoping review protocol.对现有明确减药工具在印度老年患者中的适用性进行的批判性评估：一项范围综述方案
Syst Rev. 2025 Aug 8;14(1):163. doi: 10.1186/s13643-025-02884-2.
2
Prescribing trends of fixed-dose combination of domperidone and proton-pump inhibitor across tertiary care centers in India, is the combination rational?印度三级医疗中心多潘立酮与质子泵抑制剂固定剂量组合的处方趋势，这种组合合理吗？
Indian J Pharmacol. 2025 May 1;57(3):159-165. doi: 10.4103/ijp.ijp_744_23. Epub 2025 Jul 9.
3
Comprehensive bibliographic study of the framework of complex generic drugs.复杂仿制药框架的综合文献研究。
J Taibah Univ Med Sci. 2025 Mar 7;20(2):169-177. doi: 10.1016/j.jtumed.2025.02.013. eCollection 2025 Apr.
4
Acceptability of fixed-dose combination treatments for hypertension in Kenya: A qualitative study using the Theoretical Framework of Acceptability.肯尼亚高血压固定剂量复方治疗的可接受性：一项基于可接受性理论框架的定性研究
PLOS Glob Public Health. 2025 Mar 18;5(3):e0003012. doi: 10.1371/journal.pgph.0003012. eCollection 2025.
5
Efficacy of Dapagliflozin + Sitagliptin + Metformin Versus Sitagliptin + Metformin in T2DM Inadequately Controlled on Metformin Monotherapy: A Multicentric Randomized Trial.达格列净+西他列汀+二甲双胍与西他列汀+二甲双胍治疗二甲双胍单药治疗控制不佳的2型糖尿病的疗效：一项多中心随机试验
Adv Ther. 2025 Feb;42(2):801-812. doi: 10.1007/s12325-024-03037-y. Epub 2024 Dec 5.
6
Multi-Target In-Silico modeling strategies to discover novel angiotensin converting enzyme and neprilysin dual inhibitors.多靶点计算机模拟策略发现新型血管紧张素转换酶和 Neprilysin 双重抑制剂。
Sci Rep. 2024 Jul 10;14(1):15991. doi: 10.1038/s41598-024-66230-7.
7
Assessment of knowledge, attitude and practice of fixed-dose combinations amongst attending physicians and residents: a cross-sectional evaluation.在职医生和住院医师对固定剂量复方制剂的知识、态度和实践评估：一项横断面评估。
Drugs Context. 2024 Apr 25;13. doi: 10.7573/dic.2024-2-1. eCollection 2024.
8
Expert Panel Review of Skin and Hair Dermatophytoses in an Era of Antifungal Resistance.专家组对抗真菌耐药时代的皮肤和毛发皮肤癣菌病的评估。
Am J Clin Dermatol. 2024 May;25(3):359-389. doi: 10.1007/s40257-024-00848-1. Epub 2024 Mar 18.
9
Efficacy and safety of fixed dose combination of Sitagliptin, metformin, and pioglitazone in type 2 Diabetes (IMPACT study): a randomized controlled trial.西他列汀、二甲双胍和吡格列酮固定剂量复方制剂治疗2型糖尿病的疗效与安全性（IMPACT研究）：一项随机对照试验
Clin Diabetes Endocrinol. 2024 Feb 10;10(1):3. doi: 10.1186/s40842-023-00161-6.
10
Why Pharmacovigilance of Non-steroidal Anti-inflammatory Drugs is Important in India?为什么印度的非甾体抗炎药药物警戒很重要？
Endocr Metab Immune Disord Drug Targets. 2024;24(7):731-748. doi: 10.2174/0118715303247469230926092404.
Zotero 插件